Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 69, Issue 4, 2002, Pages 213-220

  Van Agthoven, M ^a   Faber, L M ^b   Uyl de Groot, C A ^a   Sonneveld, P ^a   Verdonck, L F ^c   Willemze, R ^d   Kluin Nelemans, J C ^e   Lowenberg B ^a   Huijgens, P C ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; Cost analysis; Costs; Economics; Non Hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENIPOSIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG COST; FEMALE; HOSPITAL COST; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; VINCRISTINE;

EID: 18744392521     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02772.x     Document Type: Article

References (31)

1. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Löwenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995;16:463-470.
2. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
4. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1994;12:769-778.
5. Montserrat E, Garcia-Conde J, Vinolas N, et al. Pro-MACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: Long-term results of a multicenter randomised trial. (PETHEMA Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol 1996;57:377-383.
6. Jerkeman M, Anderson H, Cavallin-Stahl E, et al. CHOP versus MACOP-B in aggressive lymphoma - A Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10:1079-1086.
7. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: Meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001;84:303-307.
8. Bennett CL, Stinson TJ, Vogel V, et al. Evaluating the financial impact of clinical trials in oncology: Results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol 2000;18:2805-2810.
9. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med Care 2001;39:373-383.
10. Neymark N. Critical reviews of economic analyses in order to make health care decisions for cancer. Ann Oncol 1998;9:1167-1172.
11. Pfistner B, Paulus U, Glossman JP, Walshe R, Tesch H, Diehl V. Can factors influencing in-patient treatment in Hodgkin's disease be identified? Retrospective analysis of HD6 patients of the GHSG. Stud Health Technol Inform 2000:77:399-403.
12. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications on non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
13. Carbone PP, Kaplan HS, Musshoff K. Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
14. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 2001;93:22-30.
15. Doorduijn JK, van der Holt B, van der Hem KG, et al. Randomized trial of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Blood 2000;96:133a.
16. Horngren CT, Foster G. Cost Accounting: A Managerial Emphasis. New Jersey: Prentice Hall 2000.
17. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for Costing Research [in Dutch]. Amstelveen: Health Care Board, 2000.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press 1996.
19. van der Kuy A, ed. Pharmacotherapeutical Compass 1998. Amstelveen: Health Care Board 1998.
20. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press 1997.
21. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggresive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
22. Armittage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-1030.
23. Doorduijn JK, Sonneveld P. Diagnosis and treatment of non-Hodgkin lymphoma in elderly patients (in Dutch). Ned Tijdschr Geneeskd 1997;141:2152-2157.
24. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomised study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.
25. Faber LM, van Agthoven M, Uyl-de Groot CA, Lowenberg B, Huijgens PC. Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: Variation in guidelines and in practice (in Dutch). Ned Tijdschr Geneeskd 2000;144:1223-1227.
26. Bryan S, Brown J. Extrapolation of cost-effectiveness information to local settings. J Health Serv Res Policy 1998;3:108-112.
27. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease, a prospective randomised trial. Eur J Cancer 2001;37:1781-1789.
28. Stiller CA. Survival of patients with cancer. Br Med J 1989;299:1058-1059.
29. Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: Population-based results in The Netherlands. Ann Oncol 1998;9:1219-1227.
30. de Rijke JM, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, van den Brandt PA. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol 1996;7:677-685.
31. Sonneveld P, Huijgens PC, Hagenbeek A. Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma (in Dutch). Ned Tijdschr Geneeskd 1999:143:418-419.